Published in Infect Immun on May 14, 2012
Germination and amplification of anthrax spores by soil-dwelling amoebas. Appl Environ Microbiol (2012) 0.96
Toxin-independent virulence of Bacillus anthracis in rabbits. PLoS One (2014) 0.80
The central nervous system as target of Bacillus anthracis toxin independent virulence in rabbits and guinea pigs. PLoS One (2014) 0.78
In trans complementation of lethal factor reveal roles in colonization and dissemination in a murine mouse model. PLoS One (2014) 0.78
The Ins and Outs of Anthrax Toxin. Toxins (Basel) (2016) 0.77
Bacillus anthracis co-opts nitric oxide and host serum albumin for pathogenicity in hypoxic conditions. Front Cell Infect Microbiol (2013) 0.77
Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain. Sci Rep (2016) 0.77
Lethal factor, but not edema factor, is required to cause fatal anthrax in cynomolgus macaques after pulmonary spore challenge. Am J Pathol (2014) 0.77
Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax. Antimicrob Agents Chemother (2016) 0.75
Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. Antimicrob Agents Chemother (2015) 0.75
A Simple Luminescent Adenylate-Cyclase Functional Assay for Evaluation of Bacillus anthracis Edema Factor Activity. Toxins (Basel) (2016) 0.75
Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun (1991) 4.17
Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest (2003) 3.57
Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun (1986) 2.94
Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med (2009) 2.93
Immunization studies with attenuated strains of Bacillus anthracis. Infect Immun (1986) 2.63
Sequence, assembly and analysis of pX01 and pX02. J Appl Microbiol (1999) 2.53
Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol (2005) 2.45
Routine markerless gene replacement in Bacillus anthracis. Infect Immun (2006) 2.42
Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine (2001) 2.23
Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microb Pathog (1993) 2.06
Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun (2003) 2.05
Anthrax toxins cooperatively inhibit endocytic recycling by the Rab11/Sec15 exocyst. Nature (2010) 1.95
Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun (2000) 1.93
Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun (1995) 1.81
Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun (2002) 1.64
Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol Aspects Med (2009) 1.61
Membrane translocation by anthrax toxin. Mol Aspects Med (2009) 1.42
Differential proteomic analysis of the Bacillus anthracis secretome: distinct plasmid and chromosome CO2-dependent cross talk mechanisms modulate extracellular proteolytic activities. J Bacteriol (2006) 1.28
Animal models of human anthrax: the Quest for the Holy Grail. Mol Aspects Med (2009) 1.28
Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome. Infect Immun (2007) 1.28
Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening. Infect Immun (2002) 1.26
The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity. Mol Aspects Med (2009) 1.20
Progress and novel strategies in vaccine development and treatment of anthrax. Immunol Rev (2011) 1.19
Identification of strain specific markers in Bacillus anthracis by random amplification of polymorphic DNA. FEMS Microbiol Lett (2005) 1.17
Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax. Am J Pathol (2011) 1.16
The adenylyl cyclase activity of anthrax edema factor. Mol Aspects Med (2009) 1.15
Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen. Infect Immun (2006) 1.12
The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Mol Microbiol (2005) 1.08
Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model. Infect Immun (2008) 1.06
Contribution of lethal toxin and edema toxin to the pathogenesis of anthrax meningitis. Infect Immun (2011) 1.06
Commingling regulatory systems following acquisition of virulence plasmids by Bacillus anthracis. Trends Microbiol (2008) 0.97
Discovery of the anthrax toxin: the beginning of studies of virulence determinants regulated in vivo. Int J Med Microbiol (2002) 0.95
Role of purine biosynthesis in Bacillus anthracis pathogenesis and virulence. Infect Immun (2010) 0.95
HtrA is a major virulence determinant of Bacillus anthracis. Mol Microbiol (2011) 0.95
Proteomic studies of Bacillus anthracis. Future Microbiol (2009) 0.87
Lethal factor is not required for Bacillus anthracis virulence in guinea pigs and rabbits. Microb Pathog (2011) 0.87
The effect of deletion of the edema factor on Bacillus anthracis pathogenicity in guinea pigs and rabbits. Microb Pathog (2011) 0.86
Probing cellular events, one quantum dot at a time. Nat Methods (2010) 2.27
Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun (2002) 1.64
Lessons to be Learned from Recent Biosafety Incidents in the United States. Isr Med Assoc J (2015) 1.51
Protective antigen as a correlative marker for anthrax in animal models. Infect Immun (2006) 1.43
Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun (2006) 1.35
Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun (2002) 1.31
Differential proteomic analysis of the Bacillus anthracis secretome: distinct plasmid and chromosome CO2-dependent cross talk mechanisms modulate extracellular proteolytic activities. J Bacteriol (2006) 1.28
Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome. Infect Immun (2007) 1.28
Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates. Infect Immun (2004) 1.26
Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection. PLoS Pathog (2008) 1.25
Structure of trigger factor binding domain in biologically homologous complex with eubacterial ribosome reveals its chaperone action. Proc Natl Acad Sci U S A (2005) 1.24
Progress and novel strategies in vaccine development and treatment of anthrax. Immunol Rev (2011) 1.19
Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent apoptosis. Infect Immun (2006) 1.17
Identification of strain specific markers in Bacillus anthracis by random amplification of polymorphic DNA. FEMS Microbiol Lett (2005) 1.17
Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect Immun (2004) 1.16
The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis. PLoS One (2010) 1.16
Construction of a rhamnose mutation in Bacillus anthracis affects adherence to macrophages but not virulence in guinea pigs. Microb Pathog (2005) 1.15
Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen. Infect Immun (2006) 1.12
Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics (2008) 1.10
The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Mol Microbiol (2005) 1.08
Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS One (2009) 1.07
Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect Immun (2003) 1.06
Infection of glioma cells with Sindbis virus induces selective activation and tyrosine phosphorylation of protein kinase C delta. Implications for Sindbis virus-induced apoptosis. J Biol Chem (2002) 1.05
Characterization of Bacillus anthracis iron-regulated surface determinant (Isd) proteins containing NEAT domains. Mol Microbiol (2008) 1.02
The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague. PLoS One (2009) 1.01
Comparison of polyethylene glycol-conjugated recombinant human acetylcholinesterase and serum human butyrylcholinesterase as bioscavengers of organophosphate compounds. Mol Pharmacol (2006) 1.01
Antibiotics cure anthrax in animal models. Antimicrob Agents Chemother (2011) 1.00
Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine (2003) 0.99
Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J Infect Dis (2009) 0.97
Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Vaccine (2008) 0.95
HtrA is a major virulence determinant of Bacillus anthracis. Mol Microbiol (2011) 0.95
Identification of chromosomally encoded membranal polypeptides of Bacillus anthracis by a proteomic analysis: prevalence of proteins containing S-layer homology domains. Proteomics (2004) 0.94
Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol Immunother (2008) 0.93
Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine (2009) 0.92
The NheA component of the non-hemolytic enterotoxin of Bacillus cereus is produced by Bacillus anthracis but is not required for virulence. Microb Pathog (2004) 0.91
Clinical and immune responses after revaccination of israeli adults with the Lister strain of vaccinia virus. J Infect Dis (2004) 0.91
Discordance in the effects of Yersinia pestis on the dendritic cell functions manifested by induction of maturation and paralysis of migration. Infect Immun (2006) 0.91
Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood (2005) 0.91
Ribosomal crystallography: a flexible nucleotide anchoring tRNA translocation, facilitates peptide-bond formation, chirality discrimination and antibiotics synergism. FEBS Lett (2004) 0.89
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem (2006) 0.88
Proteomic studies of Bacillus anthracis. Future Microbiol (2009) 0.87
Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen. J Biol Chem (2005) 0.87
Lethal factor is not required for Bacillus anthracis virulence in guinea pigs and rabbits. Microb Pathog (2011) 0.87
The effect of deletion of the edema factor on Bacillus anthracis pathogenicity in guinea pigs and rabbits. Microb Pathog (2011) 0.86
T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague. Vaccine (2011) 0.85
Identification and characterization of novel and potent transcription promoters of Francisella tularensis. Appl Environ Microbiol (2010) 0.85
Disparity between Yersinia pestis and Yersinia enterocolitica O:8 in YopJ/YopP-dependent functions. Adv Exp Med Biol (2007) 0.84
Evaluation of protective immunity induced by Yersinia enterocolitica type-III secretion system mutants. Adv Exp Med Biol (2003) 0.83
Whole-genome immunoinformatic analysis of F. tularensis: predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response. PLoS One (2011) 0.83
Controlled concealment of exposed clearance and immunogenic domains by site-specific polyethylene glycol attachment to acetylcholinesterase hypolysine mutants. J Biol Chem (2007) 0.83
Stereoselectivity toward VX is determined by interactions with residues of the acyl pocket as well as of the peripheral anionic site of AChE. Biochemistry (2004) 0.83
Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection. Antimicrob Agents Chemother (2012) 0.82
Aging-resistant organophosphate bioscavenger based on polyethylene glycol-conjugated F338A human acetylcholinesterase. Mol Pharmacol (2008) 0.82
The aromatic "trapping" of the catalytic histidine is essential for efficient catalysis in acetylcholinesterase. Biochemistry (2002) 0.82
A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion. J Biol Chem (2012) 0.81
Involvement of TLR2 in innate response to Bacillus anthracis infection. Innate Immun (2009) 0.80
Early sensing of Yersinia pestis airway infection by bone marrow cells. Front Cell Infect Microbiol (2012) 0.80
Novel and unique diagnostic biomarkers for Bacillus anthracis infection. Appl Environ Microbiol (2009) 0.80
Macrophages play a key role in early blood brain barrier reformation after hypothermic brain injury. Neurosci Lett (2011) 0.80
A novel homogeneous immunoassay for anthrax detection based on the AlphaLISA method: detection of B. anthracis spores and protective antigen (PA) in complex samples. Anal Bioanal Chem (2013) 0.80
Host-regulated disposition of mammalian AChEs. Chem Biol Interact (2005) 0.79
Vaccination with plasmid DNA expressing the Yersinia pestis capsular protein F1 protects mice against plague. Adv Exp Med Biol (2003) 0.79
In vitro screen of bioinformatically selected Bacillus anthracis vaccine candidates by coupled transcription, translation, and immunoprecipitation analysis. Methods Mol Biol (2007) 0.79
Amino acid domains control the circulatory residence time of primate acetylcholinesterases in rhesus macaques (Macaca mulatta). Biochem J (2004) 0.79
Clusters versus affinity-based approaches in F. tularensis whole genome search of CTL epitopes. PLoS One (2012) 0.78
Overloading and removal of N-glycosylation targets on human acetylcholinesterase: effects on glycan composition and circulatory residence time. Biochem J (2002) 0.78
Polyethylene-glycol conjugated recombinant human acetylcholinesterase serves as an efficacious bioscavenger against soman intoxication. Toxicology (2006) 0.78
Identification of genes involved in Yersinia pestis virulence by signature-tagged mutagenesis. Adv Exp Med Biol (2003) 0.78
Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. Biochem J (2009) 0.78
The role of AChE active site gorge in determining stereoselectivity of charged and noncharged VX enantiomers. Chem Biol Interact (2005) 0.78
Is aromaticity essential for trapping the catalytic histidine 447 in human acetylcholinesterase? Biochemistry (2004) 0.77
Inhalation anesthetic-induced neuroinvasion by an attenuated strain of West Nile virus in mice. J Med Virol (2002) 0.77
Whole-Genome Sequencing of the Nonproteolytic Bacillus anthracis V770-NP1-R Strain Reveals Multiple Mutations in Peptidase Loci. Genome Announc (2014) 0.76
Lessons from functional analysis of AChE covalent and noncovalent inhibitors for design of AD therapeutic agents. Chem Biol Interact (2005) 0.76
A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease. Virol J (2012) 0.76
Next generation OP-bioscavengers: a circulatory long-lived 4-PEG hypolysine mutant of F338A-HuAChE with optimal pharmacokinetics and pseudo-catalytic characteristics. Chem Biol Interact (2009) 0.75
Pressure and heat inactivation of recombinant human acetylcholinesterase. Importance of residue E202 for enzyme stability. Eur J Biochem (2002) 0.75